CRISPR Editing of Stem Cell Subset Reactivates Fetal Hemoglobin for Treating Genetic Blood Disorders

Scientists in the United States have used CRISPR-Cas9 technology to edit the genomes of a specific subset of blood forming stem cells as an approach to reversing the clinical symptoms of blood disorders such as sickle cell disease (SCD) and beta-thalassemia. Beta-hemoglobinopathies are caused by gene mutations that result in abnormal production of hemoglobin.
Read more...

;